QIAGEN N.V. (NYSE:QGEN) announces CE
Mark certification of its therascreen PIK3CA RGQ PCR kit as an aid in
identifying breast cancer patients with a PIK3CA mutation. Market launch
is underway.
The FDA approved the test last year. It is used as a companion diagnostic for Novartis’ Piqray (alpelisib).
https://seekingalpha.com/news/3537588-qiagen-launches-new-breast-cancer-test-in-europe
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.